Neuro-bio welcomes Georgia Price as part of the team! Georgia is currently undertaking a DPhil at the University of Oxford studying neurodegenerative diseases after completing her undergraduate degree in Biomedical Science from the University of Sheffield. After...
On Tuesday the 5th of April, Neuro-bio’s CEO, Baroness Susan Greenfield, NED, Professor Paul Herrling and Behaviourist, Stuart Williams, held a Press Conference at the Royal College of Physicians London for the publication of their latest results in Alzheimer’s...
Neuro-Bio welcomes Linda Morgan as new Finance Manager. Linda has a wide range of experience in accountancy. After graduating from the University of Brighton with a BA (hons) degree in Accounting and Finance she went on to work for an accounting practice in Oxford...
Publishing our work in Alzheimer’s & Dementia: Translational Research & Clinical Interventions (TRCI), Neuro-Bio researchers, in collaboration with the drug discovery company Evotec SE, UCLA, and King’s College London studied the ability of their patented...
Neuro-Bio is now collaborating with Tino Rossi. Tino has over 40 years of experience in drug discovery and development having occupied roles of growing seniority and leadership in Medicinal Chemistry, Chemical Development and Preclinical Drug Discovery in...
Neuro-Bio welcomes Mark I. Butler as new COO Designate. Mark holds a Ph.D. in Pharmacology from the University of Bristol, where he completed a “bench-to-bedside” thesis focusing on the mechanisms of new antiplatelet agents. He has over ten years...
